Hepatitis C immune globulin - Cangene

Drug Profile

Hepatitis C immune globulin - Cangene

Latest Information Update: 28 Feb 2014

Price : $50

At a glance

  • Originator Cangene Corporation
  • Developer Emergent BioSolutions
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 20 Jul 2001 Cangene has stopped its phase II trial but is considering alternative approaches for further evaluation of this product
  • 20 Jul 2001 Suspended-II for Hepatitis C in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top